We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

48 hedge funds and large institutions have $15.7M invested in Theriva Biologics in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 8

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more ownership

Funds ownership: 0% → 0% (+0%)

6% less funds holding

Funds holding: 51 → 48 (-3)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

44% less capital invested

Capital invested by funds: $27.9M → $15.7M (-$12.2M)

Holders
48
Holders Change
-3
Holders Change %
-5.88%
% of All Funds
1.09%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
12
Reduced
8
Closed
6
Calls
$2.77M
Puts
–
Net Calls
+$2.77M
Net Calls Change
-$6.98M

Top Buyers

Rank Fund Capital Flow
1
William Blair & Company
William Blair & Company
Illinois
+$1.23M
2
6CM
683 Capital Management
New York
+$1.07M
3
VF
Virtu Financial
New York
+$150K
4
Citadel Advisors
Citadel Advisors
Florida
+$131K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$81.2K

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.26M
2
EDRH
Edmond de Rothschild Holding
Switzerland
-$345K
3
Millennium Management
Millennium Management
New York
-$200K
4
ECM
Element Capital Management
New York
-$171K
5
Squarepoint
Squarepoint
New York
-$85K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$38K +$6.25K +1 +13%
SLG
27
Stanley-Laman Group
Pennsylvania
$31K – – –
BA
28
Bard Associates
Illinois
$29K -$12.5K -2 -25%
State Street
29
State Street
Massachusetts
$26K – – –
SFSIG
30
San Francisco Sentry Investment Group
California
$24K – – –
KA
31
Kovack Advisors
Florida
$17K +$12.5K +2 +100%
CBA
32
Coastal Bridge Advisors
Connecticut
$16K – – –
DC
33
Davenport & Co
Virginia
$12.7K +$18.7K +3 New
HLA
34
Hamilton Lane Advisors
Pennsylvania
$12K – – –
MWM
35
Mission Wealth Management
California
$12K – – –
OAM
36
Oxford Asset Management
United Kingdom
$12K +$6.25K +1 +50%
Morgan Stanley
37
Morgan Stanley
New York
$10K -$12.5K -2 -50%
HighTower Advisors
38
HighTower Advisors
Illinois
$9K -$18.7K -3 -60%
Royal Bank of Canada
39
Royal Bank of Canada
Ontario, Canada
$9K -$6.25K -1 -33%
Bank of America
40
Bank of America
North Carolina
$8K – – –
Macquarie Group
41
Macquarie Group
Australia
$8K +$12.5K +2 New
GC
42
Guggenheim Capital
Illinois
$7K – – –
Commonwealth Equity Services
43
Commonwealth Equity Services
Massachusetts
$6K -$6.25K -1 -50%
CAN
44
Cetera Advisor Networks
California
$6K – – –
LNC
45
Lincoln National Corp
Pennsylvania
$6K +$6.25K +1 New
IP
46
Intellectus Partners
California
$5K – – –
MAM
47
Meeder Asset Management
Ohio
$3K – – –
SPIA
48
Steward Partners Investment Advisory
New York
$2K – – –
TWA
49
TCI Wealth Advisors
Arizona
$2K – – –
Bank of Montreal
50
Bank of Montreal
Ontario, Canada
$1K – – –
1
2
3

TOVX Hedge Fund Activity: Q4 2017 in Review

48 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2017, worth a combined $15.7M — down 44% from $27.9M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of TOVX and 5 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 12 added.

The largest buyer was William Blair & Company, opening a new position worth an estimated $1.23M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.26M sold.

  • 48 institutional investors held Theriva Biologics (TOVX) as of Q4 2017, down from 51 in Q3 2017.
  • Funds reported $15.7M of Theriva Biologics stock for Q4 2017, down 44% quarter-over-quarter.
  • 5 funds opened new Theriva Biologics positions in Q4 2017 and 6 closed out, a net change of -1 holder.
  • The largest Theriva Biologics buyer in Q4 2017 was William Blair & Company, an estimated $1.23M added.
  • The largest Theriva Biologics seller in Q4 2017 was Alyeska Investment Group, an estimated $1.26M sold.

Based on aggregated 13F filings for Q4 2017.